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A B S T R A C T
Some antiepileptic drugs (AEDs) have been reported to aggravate generalized seizures. We have seen
three children whose myoclonic seizures increased on starting treatment with Levetiracetam. In all
seizures aggravation was temporally associated to the introduction of the drug. All became seizure-free
onwithdrawal of levetiracetamwith a switch to an alternative antiepileptic drug and this persisted for at
least 6 months. This suggests that some children with myoclonic seizures may have an aggravation on
starting treatment with levetiracetam but this requires further studies.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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journal homepage: www.e lsev ier .com/ locate /yse izLevetiracetam (LEV) is effective in controlling focal seizures as
adjunctive therapy in adults, children and in infants and as initial
monotherapy in adultswith newly diagnosed epilepsy. Recent data
suggests that it may be effective also in idiopathic generalized
epilepsy (IGE). Some antiepileptic drugs (AEDs) may a aggravate
seizures in IGEs. Carbamazepine is known for this and lamotrigine
has been reported to aggravate myoclonic seizure.1–3 We report
three children with newly diagnosed IGEs attending our neuro-
paediatric clinic that had an important increase in seizure
frequency on starting treatment with LEV. This increase was seen
within the ﬁrst week of treatment with LEV. Seizures went into
remission when LEV was switched to an alternative.
We deﬁned aggravation as an increase in seizures bymore than
50% over baseline frequency on starting an AED without irregular
use of the medication or concomitant inappropriate lifestyle.
1. Cases
Case 1 is an 8-year-old boy, the ﬁrst child of healthy, unrelated
parents. Psychomotor development was normal. He was seen in
clinic after two generalized tonic clonic seizures and then it
became apparent that he was having early morning myoclonic
seizures. Mean seizures frequency was about 10 seizures a day.
Neurologic examination was normal. Brain MRI was normal. A
24 h-video EEG showed normal background and generalized
polyspike-wave discharges (GPSWD) inter-ictally (Fig. 1). Juvenile
myoclonic epilepsy (JME) was diagnosed and LEV started at
250 mg/day (6 mg/kg). Seizure frequency quickly increased and
exacerbated further on increasing LEV to 500 mg/day. Seizures* Corresponding author. Tel.: +86 29 84771058; fax: +86 29 84771058.
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http://dx.doi.org/10.1016/j.seizure.2012.08.008were happening up to 20 times a day and occurring randomly.
After a week on this dose he was started on sodium valproate
500 mg/day and the dose of LEV halved leading to a signiﬁcant
decrease in seizures. LEV was completed stopped after a week and
he has been in remission for up to six month since.
Case 2 is a 10-year-old boy, the ﬁrst child of healthy, unrelated
parents who had normal psychomotor development. He devel-
oped myoclonic seizures on awakening four months before
presentation and was having up to 7 episodes of myoclonus a
day. Neurologic examination was normal as was a Brain MRI.
24 h-video EEG recording showed generalised spike-wave
discharges (GSWD) and GPSWD inter-ictally (Fig. 2). JME was
diagnosed and LEVwas prescribed starting at 125 mg/day (5 mg/
kg). His seizures increased and worsened further when the dose
was increased to 250 mg/day. He was having over 10 seizures a
day. Treatment was switched to sodium valproate and he
became seizure-free.
Case 3 is also a 10-year-old boy, the ﬁrst child of healthy,
unrelated parents, with normal psychomotor development. He
was having early morning myoclonic seizures for up to 6 months
on presentation and these were happening up to 6–8 times a day.
Neurologic examination and MRI brain were normal. A 24 h-video
EEG showed GPSWD inter-ictally. JME was diagnosed and he was
also started on LEV 250 mg/day (7 mg/kg). Seizures persisted and
LEV was increased to 500 mg/day. Seizures then increased to up to
12 times a day and started to occur randomly. Treatment was
switched to sodium valproate and seizures quickly remitted.When
seen 6 months later, he was still completely seizure free.
2. Discussion
It is likely that all 3 children had JME. As typical in this
syndrome, case 1 presented after having convulsions and thenwithvier Ltd. All rights reserved.
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Fig. 1. Interictal electroencephalogram reveals paroxysmal generalised polyspike-wave discharges.
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Fig. 2. Interictal electroencephalogram reveals paroxysmal generalised polyspike-wave discharges.
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myoclonic seizures. The remaining two presented because of early
morning myoclonus.
Valproate is the usual treatment for JME but there are concerns
about it tolerability particularly in younger people and LEV has
recently been suggested as possible alternative.4,5 In China, some
parents are anxious about potential cognitive effects and weight
gain with valproate and they prefer LEV as an initial treatment in
preference to valproate when given the choice.
We report the aggravation of myoclonic seizures on starting
treatment with LEV in three children with likely JME. AEDs may
occasionally aggravate seizures in peoplewith IGEs such as JME.2
A causal and temporal relationship with starting treatment with
the offending drugs needs to be seen. Such a temporal
relationship was clearly seen in our patients. This detrimental
effect reversed with the withdrawal of LEV and initiation of
treatment with valproate. There were no untoward effects in
these patients probably related to the early recognition of theproblem. This is important as often worsening of seizures may
herald convulsions and even status epilepticus if the offending
drug is not withdrawn.
LEV is the ﬁrst and to date the only newer AED licensed for the
treatment of myoclonic seizures.6 It is a likely candidate to replace
valproate in the treatment of JME. Our observation, may suggest
that LEV, although a broad spectrum AED with an unique
mechanism of action, could aggravate myoclonic seizures in some
patients. It is difﬁcult at this stage to draw conclusions on any
potential underlyingmechanism for this reaction. In some children
with refractory epilepsy, an increase in seizure frequency was
related to the initial high doses of LEV.7 Starting dose of LEV in our
3 patients (5–7 mg/kg) was relatively low and unlikely to be
responsible. Generalized seizures when aggravated are related to
the mechanisms of action of the offending drug, particularly
sodium channel blockers and GABA-ergic drugs.7 As the putative
mechanism of action of LEV is largely unknown it is difﬁcult to
speculate about this.
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causality cannot be clearly established. Nevertheless, we feel that
our experience with these cases should be brought to the attention
of other physicians particularly as LEV is taking place as a ﬁrst line
treatment for myoclonic seizures.
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